M
Matthew F. Sammons
Researcher at Pfizer
Publications - 26
Citations - 1465
Matthew F. Sammons is an academic researcher from Pfizer. The author has contributed to research in topics: Glucagon receptor & Glucagon. The author has an hindex of 11, co-authored 25 publications receiving 643 citations. Previous affiliations of Matthew F. Sammons include University of Colorado Boulder & United States Department of Agriculture.
Papers
More filters
Posted ContentDOI
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Dafydd R. Owen,Charlotte Moira Norfor Allerton,Annaliesa S. Anderson,Lisa Aschenbrenner,Melissa Avery,Simon Berritt,Britton Boras,Rhonda D. Cardin,Anthony Carlo,Karen J. Coffman,Alyssa Dantonio,Li Di,Heather Eng,RoseAnn Ferre,Ketan S. Gajiwala,Scott A. Gibson,Samantha Elizabeth Greasley,Brett L. Hurst,Eugene P. Kadar,Amit S. Kalgutkar,Jack C. Lee,Jisun Lee,Wei Liu,Stephen W. Mason,Stephen Noell,Jonathan J. Novak,R. Scott Obach,Kevin Ogilvie,Nandini Chaturbhai Patel,Martin Pettersson,Devendra K. Rai,Matthew R. Reese,Matthew F. Sammons,Jean G. Sathish,Ravi Shankar P. Singh,Claire M. Steppan,Al E. Stewart,Jamison B. Tuttle,Lawrence W. Updyke,Patrick Robert Verhoest,Liuqing Wei,Qingyi Yang,Yuao Zhu +42 more
TL;DR: The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS-CoV-2) has become a global pandemic as discussed by the authors.
Journal ArticleDOI
Simultaneous analysis of phytohormones, phytotoxins, and volatile organic compounds in plants
Eric A. Schmelz,Juergen Engelberth,Hans T. Alborn,Phillip J. O'Donnell,Matthew F. Sammons,Hiroaki Toshima,James H. Tumlinson +6 more
TL;DR: In this paper, a simple preparation and a GC-MS-based metabolic profiling approach were used to quantify the levels of COR, salicylic acid, jasmonic acid, indole-3-acetic acid, and abscisic acid in plant tissues.
Journal ArticleDOI
A Concise Formal Synthesis of Diazonamide A by the Stereoselective Construction of the C10 Quaternary Center
TL;DR: It is shown that a close synthetic analogue of diazonamide A lacking the two chlorine atoms retains the cytotoxicity of the natural product, but does not display overt toxicity nor does it cause weight loss, change in overall physical appearance, or evidence of neutropenia in mice.
Journal ArticleDOI
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus
Angel Guzman-Perez,Jeffrey A. Pfefferkorn,Esther C.Y. Lee,Benjamin D. Stevens,Gary Erik Aspnes,Jianwei Bian,Mary Theresa Didiuk,Kevin J. Filipski,Dianna E. Moore,Christian Perreault,Matthew F. Sammons,Meihua Tu,Janice A. Brown,Karen Atkinson,John Litchfield,Beijing Tan,Brian Samas,William J. Zavadoski,Christopher T. Salatto,Judith L. Treadway +19 more
TL;DR: This candidate has lower molecular weight and lipophilicity than historical glucagon receptor antagonists, resulting in excellent selectivity in broad-panel screening, lower cytotoxicity, and excellent overall in vivo safety in early pre-clinical testing.
Journal ArticleDOI
Recent progress in the development of small-molecule glucagon receptor antagonists
TL;DR: The inhibition of glucagon-induced hepatic glucose output via antagonism of the GCGr using small-molecule ligands is a promising mechanism for improving glycemic control in the diabetic state.